Global Neutropenia Drugs Market

Neutropenia Drugs Comprehensive Study by Type (Congenital Neutropenia, Idiopathic, Cyclic Neutropenia, Autoimmune Neutropenia), By Drug type (Capsule, Injection), End User (Hospital, Clinics) Players and Region - Global Market Outlook to 2026

Neutropenia Drugs Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Neutropenia Drugs Market Scope?
Neutrophils are a type of white blood cell, it fights infection by destroying harmful bacteria and fungi that invade the body. Neutrophils are made in the bone marrow as it is the spongy tissue found in larger bones such as the pelvis, vertebrae, and ribs. It occurs when an individual has low levels of neutrophils. Additionally, it fights against infection by demolishing harmful fungi, yeast, and bacteria that attack the body. Individuals with neutropenia have a higher risk of developing crucial infections. According to the research done half of the people with cancer who receive chemotherapy develop some level of neutropenia. Neutropenia is a common side effect in people living with leukemia as well thus the demand for the drug is booming across the globe.

The Neutropenia Drugs market study is being classified by Type (Congenital Neutropenia, Idiopathic, Cyclic Neutropenia and Autoimmune Neutropenia) and major geographies with country level break-up.

The companies are exploring the market by adopting mergers & acquisitions expansions investments new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analysts at AMA predicts that Players from United States will contribute to the maximum growth of Global Neutropenia Drugs market throughout the predicted period.

Prolong Pharmaceuticals, LLC (United States), Richter Gedeon Nyrt. (Hungary), NAL Pharmaceuticals Ltd. (United States), Ligand Pharmaceuticals, Inc. (United States), Apotex Inc. (Canada), Dr. Reddy's Laboratories Limited (India), Coherus BioSciences, Inc. (United States), Biogenomics Limited (India), Cellerant Therapeutics, Inc. (United States) and Sandoz International GmbH (Germany) are some of the key players profiled in the study.

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Neutropenia Drugs market by Type, Application and Region.

On the basis of geography, the market of Neutropenia Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).




Influencing Market Trend
  • New developments to gain momentum in the global neutropenia drug

Market Drivers
  • Growing preference for chemotherapy to treat the cancer
  • Increasing risk of serious infections


Restraints
  • The adverse effect of the drugs

Challenges
  • High cost of the drugs


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Neutropenia Drugs Manufacturers, Government Regulatory and Research Organizations and End-Use Industry

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Report Objectives / Segmentation Covered

By Type
  • Congenital Neutropenia
  • Idiopathic
  • Cyclic Neutropenia
  • Autoimmune Neutropenia
By By Drug type
  • Capsule
  • Injection

By End User
  • Hospital
  • Clinics

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing preference for chemotherapy to treat the cancer
      • 3.2.2. Increasing risk of serious infections
    • 3.3. Market Challenges
      • 3.3.1. High cost of the drugs
    • 3.4. Market Trends
      • 3.4.1. New developments to gain momentum in the global neutropenia drug
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Neutropenia Drugs, by Type, By Drug type, End User and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Neutropenia Drugs (Value)
      • 5.2.1. Global Neutropenia Drugs by: Type (Value)
        • 5.2.1.1. Congenital Neutropenia
        • 5.2.1.2. Idiopathic
        • 5.2.1.3. Cyclic Neutropenia
        • 5.2.1.4. Autoimmune Neutropenia
      • 5.2.2. Global Neutropenia Drugs by: By Drug type (Value)
        • 5.2.2.1. Capsule
        • 5.2.2.2. Injection
      • 5.2.3. Global Neutropenia Drugs by: End User (Value)
        • 5.2.3.1. Hospital
        • 5.2.3.2. Clinics
      • 5.2.4. Global Neutropenia Drugs Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Neutropenia Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Prolong Pharmaceuticals, LLC (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Richter Gedeon Nyrt. (Hungary)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. NAL Pharmaceuticals Ltd. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Ligand Pharmaceuticals, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Apotex Inc. (Canada)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Dr. Reddy's Laboratories Limited (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Coherus BioSciences, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Biogenomics Limited (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Cellerant Therapeutics, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Sandoz International GmbH (Germany)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Neutropenia Drugs Sale, by Type, By Drug type, End User and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Neutropenia Drugs (Value)
      • 7.2.1. Global Neutropenia Drugs by: Type (Value)
        • 7.2.1.1. Congenital Neutropenia
        • 7.2.1.2. Idiopathic
        • 7.2.1.3. Cyclic Neutropenia
        • 7.2.1.4. Autoimmune Neutropenia
      • 7.2.2. Global Neutropenia Drugs by: By Drug type (Value)
        • 7.2.2.1. Capsule
        • 7.2.2.2. Injection
      • 7.2.3. Global Neutropenia Drugs by: End User (Value)
        • 7.2.3.1. Hospital
        • 7.2.3.2. Clinics
      • 7.2.4. Global Neutropenia Drugs Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Neutropenia Drugs: by Type(USD Million)
  • Table 2. Neutropenia Drugs Congenital Neutropenia , by Region USD Million (2015-2020)
  • Table 3. Neutropenia Drugs Idiopathic , by Region USD Million (2015-2020)
  • Table 4. Neutropenia Drugs Cyclic Neutropenia , by Region USD Million (2015-2020)
  • Table 5. Neutropenia Drugs Autoimmune Neutropenia , by Region USD Million (2015-2020)
  • Table 6. Neutropenia Drugs: by By Drug type(USD Million)
  • Table 7. Neutropenia Drugs Capsule , by Region USD Million (2015-2020)
  • Table 8. Neutropenia Drugs Injection , by Region USD Million (2015-2020)
  • Table 9. Neutropenia Drugs: by End User(USD Million)
  • Table 10. Neutropenia Drugs Hospital , by Region USD Million (2015-2020)
  • Table 11. Neutropenia Drugs Clinics , by Region USD Million (2015-2020)
  • Table 12. South America Neutropenia Drugs, by Country USD Million (2015-2020)
  • Table 13. South America Neutropenia Drugs, by Type USD Million (2015-2020)
  • Table 14. South America Neutropenia Drugs, by By Drug type USD Million (2015-2020)
  • Table 15. South America Neutropenia Drugs, by End User USD Million (2015-2020)
  • Table 16. Brazil Neutropenia Drugs, by Type USD Million (2015-2020)
  • Table 17. Brazil Neutropenia Drugs, by By Drug type USD Million (2015-2020)
  • Table 18. Brazil Neutropenia Drugs, by End User USD Million (2015-2020)
  • Table 19. Argentina Neutropenia Drugs, by Type USD Million (2015-2020)
  • Table 20. Argentina Neutropenia Drugs, by By Drug type USD Million (2015-2020)
  • Table 21. Argentina Neutropenia Drugs, by End User USD Million (2015-2020)
  • Table 22. Rest of South America Neutropenia Drugs, by Type USD Million (2015-2020)
  • Table 23. Rest of South America Neutropenia Drugs, by By Drug type USD Million (2015-2020)
  • Table 24. Rest of South America Neutropenia Drugs, by End User USD Million (2015-2020)
  • Table 25. Asia Pacific Neutropenia Drugs, by Country USD Million (2015-2020)
  • Table 26. Asia Pacific Neutropenia Drugs, by Type USD Million (2015-2020)
  • Table 27. Asia Pacific Neutropenia Drugs, by By Drug type USD Million (2015-2020)
  • Table 28. Asia Pacific Neutropenia Drugs, by End User USD Million (2015-2020)
  • Table 29. China Neutropenia Drugs, by Type USD Million (2015-2020)
  • Table 30. China Neutropenia Drugs, by By Drug type USD Million (2015-2020)
  • Table 31. China Neutropenia Drugs, by End User USD Million (2015-2020)
  • Table 32. Japan Neutropenia Drugs, by Type USD Million (2015-2020)
  • Table 33. Japan Neutropenia Drugs, by By Drug type USD Million (2015-2020)
  • Table 34. Japan Neutropenia Drugs, by End User USD Million (2015-2020)
  • Table 35. India Neutropenia Drugs, by Type USD Million (2015-2020)
  • Table 36. India Neutropenia Drugs, by By Drug type USD Million (2015-2020)
  • Table 37. India Neutropenia Drugs, by End User USD Million (2015-2020)
  • Table 38. South Korea Neutropenia Drugs, by Type USD Million (2015-2020)
  • Table 39. South Korea Neutropenia Drugs, by By Drug type USD Million (2015-2020)
  • Table 40. South Korea Neutropenia Drugs, by End User USD Million (2015-2020)
  • Table 41. Taiwan Neutropenia Drugs, by Type USD Million (2015-2020)
  • Table 42. Taiwan Neutropenia Drugs, by By Drug type USD Million (2015-2020)
  • Table 43. Taiwan Neutropenia Drugs, by End User USD Million (2015-2020)
  • Table 44. Australia Neutropenia Drugs, by Type USD Million (2015-2020)
  • Table 45. Australia Neutropenia Drugs, by By Drug type USD Million (2015-2020)
  • Table 46. Australia Neutropenia Drugs, by End User USD Million (2015-2020)
  • Table 47. Rest of Asia-Pacific Neutropenia Drugs, by Type USD Million (2015-2020)
  • Table 48. Rest of Asia-Pacific Neutropenia Drugs, by By Drug type USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific Neutropenia Drugs, by End User USD Million (2015-2020)
  • Table 50. Europe Neutropenia Drugs, by Country USD Million (2015-2020)
  • Table 51. Europe Neutropenia Drugs, by Type USD Million (2015-2020)
  • Table 52. Europe Neutropenia Drugs, by By Drug type USD Million (2015-2020)
  • Table 53. Europe Neutropenia Drugs, by End User USD Million (2015-2020)
  • Table 54. Germany Neutropenia Drugs, by Type USD Million (2015-2020)
  • Table 55. Germany Neutropenia Drugs, by By Drug type USD Million (2015-2020)
  • Table 56. Germany Neutropenia Drugs, by End User USD Million (2015-2020)
  • Table 57. France Neutropenia Drugs, by Type USD Million (2015-2020)
  • Table 58. France Neutropenia Drugs, by By Drug type USD Million (2015-2020)
  • Table 59. France Neutropenia Drugs, by End User USD Million (2015-2020)
  • Table 60. Italy Neutropenia Drugs, by Type USD Million (2015-2020)
  • Table 61. Italy Neutropenia Drugs, by By Drug type USD Million (2015-2020)
  • Table 62. Italy Neutropenia Drugs, by End User USD Million (2015-2020)
  • Table 63. United Kingdom Neutropenia Drugs, by Type USD Million (2015-2020)
  • Table 64. United Kingdom Neutropenia Drugs, by By Drug type USD Million (2015-2020)
  • Table 65. United Kingdom Neutropenia Drugs, by End User USD Million (2015-2020)
  • Table 66. Netherlands Neutropenia Drugs, by Type USD Million (2015-2020)
  • Table 67. Netherlands Neutropenia Drugs, by By Drug type USD Million (2015-2020)
  • Table 68. Netherlands Neutropenia Drugs, by End User USD Million (2015-2020)
  • Table 69. Rest of Europe Neutropenia Drugs, by Type USD Million (2015-2020)
  • Table 70. Rest of Europe Neutropenia Drugs, by By Drug type USD Million (2015-2020)
  • Table 71. Rest of Europe Neutropenia Drugs, by End User USD Million (2015-2020)
  • Table 72. MEA Neutropenia Drugs, by Country USD Million (2015-2020)
  • Table 73. MEA Neutropenia Drugs, by Type USD Million (2015-2020)
  • Table 74. MEA Neutropenia Drugs, by By Drug type USD Million (2015-2020)
  • Table 75. MEA Neutropenia Drugs, by End User USD Million (2015-2020)
  • Table 76. Middle East Neutropenia Drugs, by Type USD Million (2015-2020)
  • Table 77. Middle East Neutropenia Drugs, by By Drug type USD Million (2015-2020)
  • Table 78. Middle East Neutropenia Drugs, by End User USD Million (2015-2020)
  • Table 79. Africa Neutropenia Drugs, by Type USD Million (2015-2020)
  • Table 80. Africa Neutropenia Drugs, by By Drug type USD Million (2015-2020)
  • Table 81. Africa Neutropenia Drugs, by End User USD Million (2015-2020)
  • Table 82. North America Neutropenia Drugs, by Country USD Million (2015-2020)
  • Table 83. North America Neutropenia Drugs, by Type USD Million (2015-2020)
  • Table 84. North America Neutropenia Drugs, by By Drug type USD Million (2015-2020)
  • Table 85. North America Neutropenia Drugs, by End User USD Million (2015-2020)
  • Table 86. United States Neutropenia Drugs, by Type USD Million (2015-2020)
  • Table 87. United States Neutropenia Drugs, by By Drug type USD Million (2015-2020)
  • Table 88. United States Neutropenia Drugs, by End User USD Million (2015-2020)
  • Table 89. Canada Neutropenia Drugs, by Type USD Million (2015-2020)
  • Table 90. Canada Neutropenia Drugs, by By Drug type USD Million (2015-2020)
  • Table 91. Canada Neutropenia Drugs, by End User USD Million (2015-2020)
  • Table 92. Mexico Neutropenia Drugs, by Type USD Million (2015-2020)
  • Table 93. Mexico Neutropenia Drugs, by By Drug type USD Million (2015-2020)
  • Table 94. Mexico Neutropenia Drugs, by End User USD Million (2015-2020)
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Neutropenia Drugs: by Type(USD Million)
  • Table 106. Neutropenia Drugs Congenital Neutropenia , by Region USD Million (2021-2026)
  • Table 107. Neutropenia Drugs Idiopathic , by Region USD Million (2021-2026)
  • Table 108. Neutropenia Drugs Cyclic Neutropenia , by Region USD Million (2021-2026)
  • Table 109. Neutropenia Drugs Autoimmune Neutropenia , by Region USD Million (2021-2026)
  • Table 110. Neutropenia Drugs: by By Drug type(USD Million)
  • Table 111. Neutropenia Drugs Capsule , by Region USD Million (2021-2026)
  • Table 112. Neutropenia Drugs Injection , by Region USD Million (2021-2026)
  • Table 113. Neutropenia Drugs: by End User(USD Million)
  • Table 114. Neutropenia Drugs Hospital , by Region USD Million (2021-2026)
  • Table 115. Neutropenia Drugs Clinics , by Region USD Million (2021-2026)
  • Table 116. South America Neutropenia Drugs, by Country USD Million (2021-2026)
  • Table 117. South America Neutropenia Drugs, by Type USD Million (2021-2026)
  • Table 118. South America Neutropenia Drugs, by By Drug type USD Million (2021-2026)
  • Table 119. South America Neutropenia Drugs, by End User USD Million (2021-2026)
  • Table 120. Brazil Neutropenia Drugs, by Type USD Million (2021-2026)
  • Table 121. Brazil Neutropenia Drugs, by By Drug type USD Million (2021-2026)
  • Table 122. Brazil Neutropenia Drugs, by End User USD Million (2021-2026)
  • Table 123. Argentina Neutropenia Drugs, by Type USD Million (2021-2026)
  • Table 124. Argentina Neutropenia Drugs, by By Drug type USD Million (2021-2026)
  • Table 125. Argentina Neutropenia Drugs, by End User USD Million (2021-2026)
  • Table 126. Rest of South America Neutropenia Drugs, by Type USD Million (2021-2026)
  • Table 127. Rest of South America Neutropenia Drugs, by By Drug type USD Million (2021-2026)
  • Table 128. Rest of South America Neutropenia Drugs, by End User USD Million (2021-2026)
  • Table 129. Asia Pacific Neutropenia Drugs, by Country USD Million (2021-2026)
  • Table 130. Asia Pacific Neutropenia Drugs, by Type USD Million (2021-2026)
  • Table 131. Asia Pacific Neutropenia Drugs, by By Drug type USD Million (2021-2026)
  • Table 132. Asia Pacific Neutropenia Drugs, by End User USD Million (2021-2026)
  • Table 133. China Neutropenia Drugs, by Type USD Million (2021-2026)
  • Table 134. China Neutropenia Drugs, by By Drug type USD Million (2021-2026)
  • Table 135. China Neutropenia Drugs, by End User USD Million (2021-2026)
  • Table 136. Japan Neutropenia Drugs, by Type USD Million (2021-2026)
  • Table 137. Japan Neutropenia Drugs, by By Drug type USD Million (2021-2026)
  • Table 138. Japan Neutropenia Drugs, by End User USD Million (2021-2026)
  • Table 139. India Neutropenia Drugs, by Type USD Million (2021-2026)
  • Table 140. India Neutropenia Drugs, by By Drug type USD Million (2021-2026)
  • Table 141. India Neutropenia Drugs, by End User USD Million (2021-2026)
  • Table 142. South Korea Neutropenia Drugs, by Type USD Million (2021-2026)
  • Table 143. South Korea Neutropenia Drugs, by By Drug type USD Million (2021-2026)
  • Table 144. South Korea Neutropenia Drugs, by End User USD Million (2021-2026)
  • Table 145. Taiwan Neutropenia Drugs, by Type USD Million (2021-2026)
  • Table 146. Taiwan Neutropenia Drugs, by By Drug type USD Million (2021-2026)
  • Table 147. Taiwan Neutropenia Drugs, by End User USD Million (2021-2026)
  • Table 148. Australia Neutropenia Drugs, by Type USD Million (2021-2026)
  • Table 149. Australia Neutropenia Drugs, by By Drug type USD Million (2021-2026)
  • Table 150. Australia Neutropenia Drugs, by End User USD Million (2021-2026)
  • Table 151. Rest of Asia-Pacific Neutropenia Drugs, by Type USD Million (2021-2026)
  • Table 152. Rest of Asia-Pacific Neutropenia Drugs, by By Drug type USD Million (2021-2026)
  • Table 153. Rest of Asia-Pacific Neutropenia Drugs, by End User USD Million (2021-2026)
  • Table 154. Europe Neutropenia Drugs, by Country USD Million (2021-2026)
  • Table 155. Europe Neutropenia Drugs, by Type USD Million (2021-2026)
  • Table 156. Europe Neutropenia Drugs, by By Drug type USD Million (2021-2026)
  • Table 157. Europe Neutropenia Drugs, by End User USD Million (2021-2026)
  • Table 158. Germany Neutropenia Drugs, by Type USD Million (2021-2026)
  • Table 159. Germany Neutropenia Drugs, by By Drug type USD Million (2021-2026)
  • Table 160. Germany Neutropenia Drugs, by End User USD Million (2021-2026)
  • Table 161. France Neutropenia Drugs, by Type USD Million (2021-2026)
  • Table 162. France Neutropenia Drugs, by By Drug type USD Million (2021-2026)
  • Table 163. France Neutropenia Drugs, by End User USD Million (2021-2026)
  • Table 164. Italy Neutropenia Drugs, by Type USD Million (2021-2026)
  • Table 165. Italy Neutropenia Drugs, by By Drug type USD Million (2021-2026)
  • Table 166. Italy Neutropenia Drugs, by End User USD Million (2021-2026)
  • Table 167. United Kingdom Neutropenia Drugs, by Type USD Million (2021-2026)
  • Table 168. United Kingdom Neutropenia Drugs, by By Drug type USD Million (2021-2026)
  • Table 169. United Kingdom Neutropenia Drugs, by End User USD Million (2021-2026)
  • Table 170. Netherlands Neutropenia Drugs, by Type USD Million (2021-2026)
  • Table 171. Netherlands Neutropenia Drugs, by By Drug type USD Million (2021-2026)
  • Table 172. Netherlands Neutropenia Drugs, by End User USD Million (2021-2026)
  • Table 173. Rest of Europe Neutropenia Drugs, by Type USD Million (2021-2026)
  • Table 174. Rest of Europe Neutropenia Drugs, by By Drug type USD Million (2021-2026)
  • Table 175. Rest of Europe Neutropenia Drugs, by End User USD Million (2021-2026)
  • Table 176. MEA Neutropenia Drugs, by Country USD Million (2021-2026)
  • Table 177. MEA Neutropenia Drugs, by Type USD Million (2021-2026)
  • Table 178. MEA Neutropenia Drugs, by By Drug type USD Million (2021-2026)
  • Table 179. MEA Neutropenia Drugs, by End User USD Million (2021-2026)
  • Table 180. Middle East Neutropenia Drugs, by Type USD Million (2021-2026)
  • Table 181. Middle East Neutropenia Drugs, by By Drug type USD Million (2021-2026)
  • Table 182. Middle East Neutropenia Drugs, by End User USD Million (2021-2026)
  • Table 183. Africa Neutropenia Drugs, by Type USD Million (2021-2026)
  • Table 184. Africa Neutropenia Drugs, by By Drug type USD Million (2021-2026)
  • Table 185. Africa Neutropenia Drugs, by End User USD Million (2021-2026)
  • Table 186. North America Neutropenia Drugs, by Country USD Million (2021-2026)
  • Table 187. North America Neutropenia Drugs, by Type USD Million (2021-2026)
  • Table 188. North America Neutropenia Drugs, by By Drug type USD Million (2021-2026)
  • Table 189. North America Neutropenia Drugs, by End User USD Million (2021-2026)
  • Table 190. United States Neutropenia Drugs, by Type USD Million (2021-2026)
  • Table 191. United States Neutropenia Drugs, by By Drug type USD Million (2021-2026)
  • Table 192. United States Neutropenia Drugs, by End User USD Million (2021-2026)
  • Table 193. Canada Neutropenia Drugs, by Type USD Million (2021-2026)
  • Table 194. Canada Neutropenia Drugs, by By Drug type USD Million (2021-2026)
  • Table 195. Canada Neutropenia Drugs, by End User USD Million (2021-2026)
  • Table 196. Mexico Neutropenia Drugs, by Type USD Million (2021-2026)
  • Table 197. Mexico Neutropenia Drugs, by By Drug type USD Million (2021-2026)
  • Table 198. Mexico Neutropenia Drugs, by End User USD Million (2021-2026)
  • Table 199. Research Programs/Design for This Report
  • Table 200. Key Data Information from Secondary Sources
  • Table 201. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Neutropenia Drugs: by Type USD Million (2015-2020)
  • Figure 5. Global Neutropenia Drugs: by By Drug type USD Million (2015-2020)
  • Figure 6. Global Neutropenia Drugs: by End User USD Million (2015-2020)
  • Figure 7. South America Neutropenia Drugs Share (%), by Country
  • Figure 8. Asia Pacific Neutropenia Drugs Share (%), by Country
  • Figure 9. Europe Neutropenia Drugs Share (%), by Country
  • Figure 10. MEA Neutropenia Drugs Share (%), by Country
  • Figure 11. North America Neutropenia Drugs Share (%), by Country
  • Figure 12. Global Neutropenia Drugs share by Players 2020 (%)
  • Figure 13. Global Neutropenia Drugs share by Players (Top 3) 2020(%)
  • Figure 14. Global Neutropenia Drugs share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Prolong Pharmaceuticals, LLC (United States) Revenue, Net Income and Gross profit
  • Figure 17. Prolong Pharmaceuticals, LLC (United States) Revenue: by Geography 2020
  • Figure 18. Richter Gedeon Nyrt. (Hungary) Revenue, Net Income and Gross profit
  • Figure 19. Richter Gedeon Nyrt. (Hungary) Revenue: by Geography 2020
  • Figure 20. NAL Pharmaceuticals Ltd. (United States) Revenue, Net Income and Gross profit
  • Figure 21. NAL Pharmaceuticals Ltd. (United States) Revenue: by Geography 2020
  • Figure 22. Ligand Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Ligand Pharmaceuticals, Inc. (United States) Revenue: by Geography 2020
  • Figure 24. Apotex Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 25. Apotex Inc. (Canada) Revenue: by Geography 2020
  • Figure 26. Dr. Reddy's Laboratories Limited (India) Revenue, Net Income and Gross profit
  • Figure 27. Dr. Reddy's Laboratories Limited (India) Revenue: by Geography 2020
  • Figure 28. Coherus BioSciences, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Coherus BioSciences, Inc. (United States) Revenue: by Geography 2020
  • Figure 30. Biogenomics Limited (India) Revenue, Net Income and Gross profit
  • Figure 31. Biogenomics Limited (India) Revenue: by Geography 2020
  • Figure 32. Cellerant Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Cellerant Therapeutics, Inc. (United States) Revenue: by Geography 2020
  • Figure 34. Sandoz International GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 35. Sandoz International GmbH (Germany) Revenue: by Geography 2020
  • Figure 36. Global Neutropenia Drugs: by Type USD Million (2021-2026)
  • Figure 37. Global Neutropenia Drugs: by By Drug type USD Million (2021-2026)
  • Figure 38. Global Neutropenia Drugs: by End User USD Million (2021-2026)
  • Figure 39. South America Neutropenia Drugs Share (%), by Country
  • Figure 40. Asia Pacific Neutropenia Drugs Share (%), by Country
  • Figure 41. Europe Neutropenia Drugs Share (%), by Country
  • Figure 42. MEA Neutropenia Drugs Share (%), by Country
  • Figure 43. North America Neutropenia Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Prolong Pharmaceuticals, LLC (United States)
  • Richter Gedeon Nyrt. (Hungary)
  • NAL Pharmaceuticals Ltd. (United States)
  • Ligand Pharmaceuticals, Inc. (United States)
  • Apotex Inc. (Canada)
  • Dr. Reddy's Laboratories Limited (India)
  • Coherus BioSciences, Inc. (United States)
  • Biogenomics Limited (India)
  • Cellerant Therapeutics, Inc. (United States)
  • Sandoz International GmbH (Germany)
Select User Access Type

Key Highlights of Report


Apr 2021 226 Pages 52 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Neutropenia Drugs Market Quantitative research analysis
Global Neutropenia Drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Global Neutropenia Drugs market is expected to see a growth of % during projected year 2020 to 2026.
The prominent players of Global Neutropenia Drugs market are Prolong Pharmaceuticals, LLC (United States), Richter Gedeon Nyrt. (Hungary), NAL Pharmaceuticals Ltd. (United States), Ligand Pharmaceuticals, Inc. (United States), Apotex Inc. (Canada), Dr. Reddy's Laboratories Limited (India), Coherus BioSciences, Inc. (United States), Biogenomics Limited (India), Cellerant Therapeutics, Inc. (United States) and Sandoz International GmbH (Germany), to name a few.
In this highly competitive & fast evolving Neutropenia Drugs industry, the top strategic priorities would remain consistent like innovation, R&D and M&A.

Know More About Global Neutropenia Drugs Market Report?

Have a Query? Click Here

Other Related Reports

Multimodal Imaging Comprehensive Study by Type (Systems, Software, Reagents), Application (Neuropsychiatry, Cardiology, Oncology, Ophthalmology, Others), Technology (PET-CT Systems, SPECT-CT Systems,...
$ 3450
Cinacalcet Comprehensive Study by Type (30 mg Tablets, 60 mg Tablets), Application (Hospitals, Medical Research Center, Pharmaceutical Factory, Others), Distribution Channel (Hospitals, Retail Pharma...
$ 3500
Olmesartan Medoxomil  Comprehensive Study by Type (20mg, 40mg), Application (Hypertension, Heart Attacks, Kidney Problems), Drugs (Generic Drugs, Brand Name Drugs), Distribution Channel (Hospitals Ph...
$ 3350
Solifenacin Succinate Drug Comprehensive Study by Type (Idiopathic Bladder Overactivity, Neurogenic Bladder Overactivity), Form (Tablet, Suspension), End User (Hospitals, Clinics), Dosage Availabilit...
$ 3500
Zolmitriptan Comprehensive Study by Type (Nasal Spray, Orally Disintegrating Tablets, Tablets, Others), Patient Age (Children (below 12 years), Adult), Dosage (2.5 mg, 5 mg), Distribution (Hospital ...
$ 3350
Antiprotozoal drugs Comprehensive Study by Type (Chloroquine, Pyrimethamine, Mefloquine, Hydroxychloroquine, Metronidazole, Atovaquone, Others), Application (Healthcare and Hospital, Others), Form (L...
$ 3350